Erik MEREDITH,Qi-Ying HU,Gary KSANDER,Lauren G. MONOVICH,Julien PAPILLON,Christoph SCHUMACHER
申请号：
MX2014011700
公开号：
MX354022B
申请日:
2011.01.13
申请国别(地区):
MX
年份:
2018
代理人:
摘要：
The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3； R is hydrogen or --C(O)N(R<；sub>；a<；/sub>；)(R<；sub>；b<；/sub>；) wherein R<；sub>；a<；/sub>； and R<；sub>；b<；/sub>； are independently --(C<；sub>；1<；/sub>；-C<；sub>；4<；/sub>；) alkyl, or --(C<；sub>；1<；/sub>；-C<；sub>；4<；/sub>；) alkyl-(C<；sub>；5<；/sub>；-C<；sub>；7<；/sub>；) aryl, wherein each of R<；sub>；a<；/sub>； and R<；sub>；b<；/sub>； is optionally substituted by --(C<；sub>；1<；/sub>；-C<；sub>；4<；/sub>；) alkoxy； R<；sub>；1<；/sub>；, R<；sub>；2<；/sub>；, and R<；sub>；3<；/sub>；, are independently hydrogen, halogen, cyano or --(C<；sub>；6<；/sub>；-C<；sub>；10<；/sub>；) aryl, wherein said --(C<；sub>；6<；/sub>；-C<；sub>；10<；/sub>；) aryl is optionally substituted by halogen, with the proviso that no more than one of R<；sub>；1<；/sub>；, R<；sub>；2<；/sub>；, and R<；sub>；3<；/sub>； is hydrogen； and R<；sub>；4<；/sub>； and R<；sub>；5<；/sub>； are hydrogen； or a pharmaceutically acceptable salt thereof.La presente invención se refiere a un compuesto en forma de sal de di-fosfato ácido de 4-[(5R)-6,7-dihidro-5H-pirrolo-[1,2-c]-imid azol-5-i)]-3-fluorobenzonitrilo.
